Vericel Corp. (NASDAQ:VCEL) saw unusually-high trading volume on Wednesday . Approximately 186,882 shares changed hands during mid-day trading, an increase of 57% from the previous session’s volume of 118,813 shares.The stock last traded at $2.19 and had previously closed at $2.17.

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC raised Vericel Corp. from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Friday, March 11th. Bank of America Corp. lowered Vericel Corp. from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 5th. Finally, Ladenburg Thalmann reissued a “buy” rating on shares of Vericel Corp. in a research note on Saturday, March 12th.

The company’s market capitalization is $49.58 million. The firm’s 50 day moving average price is $2.52 and its 200-day moving average price is $2.81.

Vericel Corp. (NASDAQ:VCEL) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.17. The firm had revenue of $14.10 million for the quarter, compared to analysts’ expectations of $11.60 million. On average, equities research analysts expect that Vericel Corp. will post ($0.79) earnings per share for the current year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.